Efficacy of Dexmedetomidine As an Adjuvant to Bupivacaine in Pericapsular Nerve Group Block in Hip Replacement Surgeries

ConditionPENG Block
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-90
SponsorAssiut University

About this trial

Our aim will be to investigate the efficacy of dexmedetomidine as an adjuvant to bupivacaine in ultrasound guided pericapsular nerve group (PENG) block for postoperative analgesia in hip replacement surgeries.

* Our primary outcome of the study: total amount of postoperative morphine consumption in the first 24h postoperative. * Our secondary outcome of the study: postoperative analgesia assessed by pain score (by Visual Analog Scale)

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged from 18 years to 90 years

Gender : both males and females

BMI less than 35 kg/m2

Patients with American society of anesthesiologists (ASA) classification class I , II or III

Disqualifiers

Patient declining to give written informed consent

Patient with infection at the site of injection

Patient with coagulopathy

Patients with known allergy to used medications.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ultrasound guided Pericapsular Nerve Group Block

    Procedure/Surgery

    With the patient in the supine position and the leg slightly abducted, a curvilinear transducer (2.5-7.5 MHz) is prepared with sterile conduction gel and covered with a sterile probe cover. The transducer is placed transversely over the anterior superior iliac spine (ASIS), then aligned with the pubic ramus and rotated approximately 45° parallel to the inguinal crease. The probe is slid medially to identify key landmarks: the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), iliopsoas tendon, femoral artery, and femoral nerve. Sliding the probe distally or tilting caudally exposes the femoral head. A 20-22 gauge echogenic needle (100 mm) is inserted in-plane from lateral to medial, targeting the plane between the psoas tendon and the pubic ramus. the anesthetic agent is deposited to lift the psoas tendon while avoiding tendon puncture.

  • Isobaric Bupivacaine 0. 25%

    Drug

    group c will receive PENG block with only 20ml isobaric bupivacaine 0.25%

  • 20 ml isobaric bupivacaine 0.25% and 1.5μg/kg dexmedetomidine

    Drug

    group D will receive PENG block with 20 ml isobaric bupivacaine 0.25% and 1.5μg/kg dexmedetomidine

  • the ultrasound machine with curvilinear transducer (high -frequency probe, 2.5Mhz to 7.5Mhz)

    Device

    the two groups will receive the PENG block under ultrasound guidance

  • a standard echogenic 20-22 gauge 100mm needle

    Device

    the two groups will receive the PENG block using a standard echogenic 20-22 gauge 100mm needle

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: group CActive comparator 4 interventions
Group B: group DActive comparator 4 interventions

Trial outcomes

Primary outcomes

1

total amount of postoperative morphine consumption in the first 24h postoperative.

Time frame
within the first 24 hours postoperatively

Secondary outcomes

1

the intensity of postoperative pain assessed by the Visual Analog Scale for pain

the intensity of postoperative pain assessed by the Visual Analog Scale for pain , which was scored from 0 to 10 where 0= no pain and 10 = the worst pain imaginable at 0,2,4,6,8,10,12,16,24 hours post-operatively to evaluate acute pain

Time frame
within the first 24 hours postoperatively

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: